Article abstract-With a new method we measured the saturated very long chain fatty acids in the plasma of adrenoleukodystrophy (ALD) hemizygotes, ALD heterozygotes, and controls. ALD hemizygotes showed increased levels of hexacosanoate (C26 fatty acid) which represented 0.081 2 0.0066% (SEM) of total Fdtty acids, compared to 0.015 ? 0.0032% in the controls. C25, C24, and C23 fatty acids were also increased, but the C22 and C20 fatty acids were normal. C26 levels were also increased in most ALD heterozygotes, with a mean level 0.057 2 0.0063% of total fatty acids. The technique can be used for diagnosis and carrier identification, and in the evaluation of therapy.
Methods and materials. The diagnosis of ALD was based on clinical history, neurologic examination, computed tomography (CT) scan, tests of adrenal functions, and a C26:C22 fatty acid ratio in cultured skin fibroblasts of 0.4 or higher.11J2 Obligate heterozygotes were mothers of patients with ALD or AMN, who also had at least one other affected relative. Others were designated by clonal analysis if clones of cultured skin fibroblasts demonstrated two types of cells: one with a normal fatty acid pattern, the other with a pattern characteristic of ALD h e m i z y g~t e s .~~J~ Dr. Barbara Migeon kindly provided the fibroblast clones.
In addition to the ALD-AMN hemizygotes and obligate heterozygotes, we studied two control groups: 22 persons 12 to 55 years old with no known disease, and 28 persons with different neurologic or metabolic diseases.
Samples (5 to 10 ml) of venous blood were added to heparinized test tubes. Plasma was separated within 2 hours and then frozen at -10" C. Most samples were obtained before breakfast. Some plasma samples were obtained in other parts of the United States or Europe, and mailed from a distance in containers filled with dry ice.
Fatty acid methyl esters were prepared as described elsewhere."J2 
. Saturated very long chain fatty acids in the plasma (A) of a 16-year-old normal male; (E) of a 12-yearold patient with adrenoleukodystrophy. The gas-liquid chromatography method and retention times are described in the text. A t the time indicated by the arrow, the sensitivity of the recording system was increased l6-fold, thus increasing the size of the peaks for the C25 and C26 fatty acids by that factor. The identity of the unlabeled peaks has not been established. Note that the C25 and C26 peaks are much higher in the A L D sample, and that in the ALD sample the C24 peak is larger than (222, while the reverse is true for the control sample. While in this tracing the C24:l peak in the ALD sample is higher than in the control, this was not true for the other A L D patients (see text).
The purified fatty acid methyl esters were dissolved in 100 pl of hexane, and 2.0 p1 was injected into a Hewlett Packard 5880A splitless injection port onto a 12-meter SP-2100 fused Silica Gel capillary column with a n inside diameter of 0.2 mm. Injection port temperature was 250" C; detector temperature was 300" C. The oven initial temperature was 150" C. After 2 minutes it was raised to 285" C at 10" per minute and maintained there for 5 minutes. Peaks were identified by co-chromatography with authentic standards in at least three systems (figure 1); the C26 fatty acid was also identified by combined mass spectrometry (Dr. Catherine Fenselau). Retention times for C20, C22, C23, C24, C25, and C26 fatty acids were 8.89,9.62,10.38,11.17,11.75, and 12.54 minutes, respectively, and were constant to within * 0.02 minutes. The peaks were measured with a Hewlett-Packard 5880 A Level 4 integrator and expressed as percentage of total fatty acids with chain length of 14 carbons or more. Standard deviations of the differences between duplicate determinations were ll to 13%.
To measure the very long chain fatty acid content in the major lipid fractions, a n aliquot of the washed total lipid extract was taken to dryness under nitrogen and subjected to alkaline methanolysis by adding 1 mlO.21 N methanolic NaOH and 2 ml chloroform for 1 hour at room temperature. This treatment released fatty acids from triglycerides and glycerophospholipids. Cholesterol esters were partially split, while sphingolipids remained intact. The extract was then subjected to Folch partition;I5 lipids in the washed lower phase were applied to a 3.0 x 0.5 cm Unisil column, and eluted with 7 ml each of hexanehenzene 6:4, chloroform, acetoneimethanol 9: 1, and methanol. The first fraction contained fatty acid methyl esters and unhydrolyzed cholesterol esters. The acetone/methanol fraction contained mainly glycolipids, and the methanol fraction mainly sphingomyelin. Cholesterol ester, glycolipid and sphingomyelin fractions were hydrolyzed with 1.5 ml 1 N methanolic HC1 at 75" C overnight. The cholesterol ester fraction was dissolved in 50 pl benzene before methanolysis. The methyl esters were analyzed by gas-liquid chromatography as described above.
Results. Diurnal variation ofplasma levels of very long chain fatty acids. Diurnal variation of very long chain fatty acids was studied in two normal persons, two patients with ALD, and one patient with AMN ( figure 2) . The values for the two ALD patients were the averages for two 3-day periods. The other studies were made on a single day. All The C22:C20 ratios showed no significant differences; ie, C22 fatty acid levels were not altered in comparison to C20. In contrast, the means of the C23:C22, C24:C22, C25:C22, and C26:C22 ratios were abnormally high in the ALD hemizygotes and heterozygotes. Differences between control groups and ALD groups gave p values less than 0.001 for all of these ratios.
The degree of abnormality of these ratios increased with the fatty acid chain length: The C26:C22 and the C25:C22 ratios in ALD hemizygotes were 4.5 to 5 times control; for the C24:C22 ratio the difference was twofold, and the C23:C22 ratio difference was 50%. For the ALD heterozygote, the increase in the C25:C22 and the C26:C22 ratios was about half of that in the hemizygote. The difference between the C26:C22 ratios for ALD heterozygotes and hemizygotes gave p values of less than 0.001, but that between the C25:C22 ratios was not significant.
The results for the patients with diseases other than ALD or AMN did not differ from normal.
Not shown in the tables were values of C24:l (nervonic acid). The mean plasma levels for this fatty acid, expressed as percentage of total fatty acids, were 0.679 t 0.062 (SEMI for normals, 0.796 2 0.082 for the ALD hemizygote, and 0.507 f 0.110 for the ALD heterozygote. These differences were not statistically significant. The mean level for the patients with other neurologic or metabolic disease was 1.004 ? 0.087, significantly higher ( p < 0.01) than the means in the normals or ALD heterozygotes.
Some ALD patients and heterozygotes also showed peaks corresponding to C28, C30, or C32 fatty acids. These peaks were small and were not quantitated.
Although there were significant differences between mean values, some individual results over- Distribution of very long chain fatty acids in different lipid classes. Both controls and ALD cases showed the highest percentage of very long chain fatty acids in the glycolipid and in the sphingomyelin fractions, and the C24 and C26 levels in both fractions were significantly increased in the ALD samples. ALD patients also showed increased very long chain fatty acid levels in the "alkaline methanolized fraction," which includes mainly glycerophosphatides and triglycerides. The ALD plasma cholesterol ester fractions did not show a n increased percentage of very long chain fatty acids.
Comparison of changes in ALD plasma and cultured skin fibroblasts. We have studied the fatty acids of both cultured skin fibroblasts and plasma in 56 persons (figure 4). The C26:C22 ratio in plasma was about one-tenth of that in fibroblasts, and the alterations in controls, ALD heterozygotes, and ALD hemizygotes were similar. All 14 ALD hemizygotes had ratios more than two standard deviations above the control mean in both tissues and all 26 controls showed normal ratios. The 16 heterozygotes showed more variability. Three heterozygotes had normal plasma C26:C22 ratios, and four had normal ratios in skin fibroblasts. Nine heterozygotes had increased ratios in both samples. Heterozygotes with normal plasma ratios had increased ratios in the fibroblasts or vice versa.
Discussion. Plasma levels of very long chain fatty acids. We found a statistically significant increase in plasma levels of saturated very long chain fatty acids in patients with ALD or AMN and in carriers. The abnormality was most striking for the C25 and C26 and less so for the C24 and C23 fatty acids.
The absolute plasma levels of the very long chain fatty acids were low: In ALD patients they made up 0.08% of total fatty acids compared to 0.014% in controls. These low levels probably ac- The diagnoses of Pelizaeus-Merzbacher disease were made on the basis of clinical criteria and have not been confirmed pathologically. The patients with leukodystrophy of unknown type are sibs with clearly progressive disability and severe destruction of white matter on CT scan. Sphingolipidoses have been ruled out by enzyme assays. count for the fact that the abnormalities were not described earlier. The capillary gas-liquid chromatography technique (as opposed to the more commonly used packed column technique) is Valuable since it gives clearly separated peaks and reproducible retention times. The conditions used are not suitable for the separation of shorter chain or unsaturated fatty acids, and the very long chain alpha hydroxy fatty acids are excluded in the thinlayer chromatography separation of fatty acid methyl esters.
Use of plasma assay for diagnosis. A technique that permits the diagnosis of ALD with less than 1 ml of plasma is more useful than previous approaches, but there are limitations. The type, nature, and conditions of the gas-liquid chromatography procedure must be precisely specified.
Conditions suitable for the more common fatty acids do not permit quantitation of very long chain fatty acids. The low absolute level requires care to exclude contaminants and to test reproducibility. The mean of the plasma levels of very long chain fatty acids is abnormal in both ALD hemizygotes and heterozygotes. However, the mean level does not provide information about the degree of overlap, or the occurrence of false positives or of false negatives. Levels of C26 fatty acids were high in 5 of 50 controls: cases 1 and 11 in table 1A and cases 3, 14, and 19 in table 1B. However, other results were normal in these subjects, and assessment of all measurements sets them apart from the ALD cases.
In the ALD hemizygotes, we did not encounter false negatives for C26 levels, and the combined use of all six criteria gave reliable identification. Two cases (cases 1 and 10, table 1D) were boys, aged 4 and 12, respectively, who were free of demonstrable adrenal or brain disease but were brothers of patients with proven ALD. The C26:C22 ratios in their cultured skin fibroblasts were abnormal (0.812 and 0.700), and we classified them as presymptomatic ALD. Our series is still small, and we may yet encounter false negatives or false positives. We therefore perform both the fibroblast and the plasma assays for diagnosis.
Some heterozygotes showed plasma elevations of very long chain fatty acids that were as marked as those in the hemizygotes, and which we also observed in cultured skin fibroblasts heterozygotes had normal or borderline plasma values (cases 5, 7, 13, and 14, table 1C). However, three of these cases had abnormal C26:C22 ratios in fibroblasts: 0.348, 0.335, and 0.336 for cases 5, 7, and 13, respectively, compared to a normal ratio of 0.077 & 0.032. Conversely, case 2 showed a borderline C26:C22 ratio in cultured skin fibroblasts (0.1601, while most of the parameters for the plasma very long chain fatty acids were abnormal. For the identification of the heterozygote it is therefore important to study both fibroblasts and plasma.
T h e metabolic defect i n ALD. The basic metabolic defect in ALD is unknown. The original observation that the accumulation of very long chain fatty acids was most prominent in the cholesterol ester fractionfi-s led to the hypothesis that there was a defect in a specific cholesterol esterase. However, the activities of cholesterol esterases were normalL6J7 and the very long chain fatty acid The values shown for case 5 represent the mean of 4 determinations on separate plasma samples; the values for cases 11, 15, and 17 represent the means of 16, 4, and 6 determinations, respectively. A packed rather than a capillary gasliquid chromatography column was used for the analysis of the sample from case 3. The values marked with a double asterisk differ from control with a p value < 0,001. The value marked with a single asterisk differs from control with a p value < 0.01. excess is not confined to the cholesterol esters. It has also been demonstrated in gangliosides,6J8 sphingomyelins,ll and free fatty acids,s suggesting that the defect involves metabolism of the very long chain fatty acids themselves. Their accumulation in the cholesterol ester fraction of the cerebral white matter and adrenal cortex could be secondary. Plasma low-density lipoproteins are precursors of adrenal c h o l e s t e r~l ,~~ and free fatty acids seem to be the precursors of cholesterol ester fatty acids in both brainz0 and adrenal gland. 21 Our new observations provide further evidence for the hypothesis that the primary defect involves the metabolism of very long chain fatty acids, since the plasma cholesterol ester fraction was not abnormal, and the abnormal fatty acids were associated with a variety of other lipid classes (table 2). The nature of this presumed abnormality of fatty acid metabolism is unknown. We are evaluating a possible abnormality of a peroxisomal poxidation ~y s t e m .~ The fatty acid ratios (figure 3) suggest that the abnormality involves mainly C25 and C26 saturated fatty acids, with lesser involvement of C24 and C23 fatty acids, and no alteration of C22 or C20 fatty acid metabolism.
Exogenous or endogenous origin of very long chain fatty acids. It is of practical significance to determine whether the accumulated fatty acids are of exogenous or endogenous origin. If exogenous, it may be useful to restrict dietary very long chain fatty acids. C25 and C26 fatty acids are constituents of plant cutin,2z and the average daily American diet contains approximately 15 to 40 mg of C26 fatty acid (Moser AE and Moser HW, unpublished observation). We showed that orally administered deuterated C26 fatty acid was incorporated into the brain cholesterol esters of one ALD patient.23 However, endogenous synthesis of very long chain fatty acids takes place in the nervous and it is not yet possible to assess the relative importance of exogenous and endogenous sources. The patterns of plasma changes also provide some leads. Excessive C26, C25, and C24 levels were noted in ALD heterozygotes and in hemizygotes, but not in patients with advanced neurologic disability from other causes, suggesting that the plasma abnormalities are not the consequence of myelin breakdown. Similarly, plasma C24:l levels were not increased in ALD, although C24:l fatty acid makes up 40% of the nonhydroxy fatty acids in myelin cerebrosides, compared t o 3.5% and 1% for C25 and C26. 25 If the elevated plasma very long chain fatty acids were derived from disintegrating myelin, there should be a greater excess of C24:l than of C25 and C26, whereas the reverse was true. For these reasons we think it likely that most of the excess long chain fatty acids in ALD plasma are of dietary origin.
Implications for therapeutic trials. The possihility that the very long chain fatty acids accumulated in ALD are of dietary origin provides the rationale for a therapeutic trial of the effect of dietary restrictions, which we are now conducting. The observation that plasma very long chain fatty acid levels are elevated in ALD is of key importance to this therapeutic trial. Periodic measurements of plasma fatty acids may help determine whether the dietary restriction can reduce the "body burden" of very long chain fatty acids, may help assess the degree to which the patients have followed the diet, and provide additional insights about disease mechanism.
